March 26, 2026
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
Daiichi Sankyo has entered a strategic collaboration with Tempus AI to expedite the clinical development and differentiation of an antibody drug conjugate (ADC) programme in the field of oncology.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







